Amgen moves more Phase 3 trials for a monthly weight-loss drug into view, intensifying pressure on leaders like Eli Lilly and Novo Nordisk

Obesity drug competition is getting louder, with Amgen indicating major clinical momentum in a space dominated in recent years by Eli Lilly and Novo Nordisk. A recent market report pointed to Amgen’s weight-loss program as particularly noteworthy because it has multiple late-stage studies running at the same time, framed as part of a broader push to expand access and reshape how patients receive treatment.

According to the report, Amgen’s monthly weight-loss candidate has six Phase 3 trials in progress. Phase 3 trials are the final, large-scale studies typically used to support regulatory submissions, and running them concurrently can accelerate the timeline for results and potential approvals. The key detail for investors and clinicians in this framing is the “monthly” dosing schedule, which would differ from the more established weekly injection regimens used for some of the current leading products.

The report’s comparison is direct: it positions the Amgen development plan as a potential challenger to the Eli Lilly and Novo Nordisk weight-loss franchises. Those companies are widely associated with high-profile glucagon-like peptide-1 (GLP-1) therapies used for obesity and related metabolic conditions. GLP-1 medicines can help reduce appetite and support weight loss, but their market standing has also been shaped by manufacturing capacity, long-running trials, and the emergence of competitors.

While the report emphasizes trial count and dosing frequency, it does not, in the information provided here, specify which particular endpoints are being targeted across those Phase 3 studies, how the populations differ, or what results, if any, have been observed to date. It also does not detail the regulatory path, such as whether Amgen plans to file in a specific jurisdiction first, or whether results from particular Phase 3 studies would be prioritized for an initial application.

Even without those specifics, the strategic message is clear: the ability to move many patients through late-stage studies can matter in a market where demand is high and timelines are watched closely. If the monthly dosing concept holds up clinically, it could appeal to patients who prefer less frequent injections, and to providers managing adherence and long-term persistence. Companies competing in this area often view adherence as a key determinant of both real-world effectiveness and eventual payer coverage outcomes.

For Eli Lilly, Novo Nordisk, and Amgen, the obesity market is also about more than one drug. It is a pipeline battleground that increasingly includes combinations of hormones and next-generation formulations intended to improve tolerability, broaden eligibility, or reduce side effects. That means a challenger with a distinct dosing schedule is not just competing on weight-loss efficacy, but also on the practical day-to-day experience of therapy.

There is also a sequencing element. Leaders like Lilly and Novo Nordisk have built momentum with product launches and ongoing research, so a new entrant’s ability to quickly produce Phase 3 evidence may translate into faster competitive pressure on prescribing patterns and contract negotiations. The market report’s framing that Amgen is “coming for” patients underscores that competitive narrative, even though it stops short of disclosing any concrete displacement scenarios.

Still, major uncertainties remain based on the limited disclosed information in the cited report. It is not stated here what Amgen’s Phase 3 trials have shown so far, what the primary endpoints are, or whether monthly dosing introduces tradeoffs in efficacy or safety versus existing weekly options. Those are the factors regulators, payers, and clinicians would need to evaluate before any shift in standard of care could be justified.

Investors and industry observers will likely focus next on formal clinical updates tied to those Phase 3 studies, including whether results support broad label expansion and how dosing frequency plays out in longer-term outcomes. For Eli Lilly and Novo Nordisk, watchpoints include continued readouts from their own obesity pipelines and any efforts to differentiate through combinations, outcomes data, or next-generation delivery mechanisms that could reinforce their position if a monthly alternative approaches approval.